KHC

The headline FY2025 net loss of -$5.85B (EPS -$4.93) looks alarming but is overwhelmingly non-cash: management's MD&A discloses $6.7B of goodwill and $2.6B of intangible impairments ($9.3B combined), more than the entire reported loss. Underneath, the business still generated $4.46B of operating cash flow (up 6.6% YoY) and ~$3.7B of free cash flow after $801M of capex — comfortably funding the $1.90B dividend and $436M of buybacks. The balance sheet is sound: liabilities/equity of 0.96x, cash up 96% to $2.62B, and current assets ($10.1B) exceeding current liabilities ($8.78B). On price the negative P/E is meaningless; P/S of 1.1x and a high single/low double-digit FCF yield on the $27.0B market cap mark this as a deep-value, income-oriented name.

The problem is durability of the top line. Revenue has now declined for a second straight year to $24.9B (-3.5% YoY) and is down from a $26.6B FY2023 peak — a slow, persistent erosion rather than a one-off. The impairments are management effectively conceding that brand and franchise value is worth materially less than carried. The MD&A and Risk Factors point to why: intense private-label competition forcing pricing concessions, pricing actions that 'negatively impacted market share,' tariff-driven supply-chain inflation, SNAP benefit reductions under the OBBBA that could cut demand from a core consumer, and shifting health/wellness preferences including weight-loss-drug-related consumption changes. The FD&C color-removal commitment adds reformulation execution risk.